ANEB Anebulo Pharmaceuticals
- 3.000
- -0.040-1.32%
Anebulo Pharmaceuticals News
We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Needs To Drive Business Growth Carefully
Anebulo Pharmaceuticals: Strong Buy Rating Amid Promising Clinical Advances and Rapid FDA Track
New Debt & Financing Risk for Anebulo Pharmaceuticals, Inc. – What's the Latest?
Substance Use Disorder Company Narrows Q2 Net Loss, Reports Progress On Cannabinoid Intoxication Drug
The biopharmaceutical company Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) reported its second quarter financial results on Tuesday for the three months ended Dec. 31, 2023,The company's primary focus
Anebulo Pharmaceuticals Announces Richie Cunningham As Chief Executive Officer
Anebulo Pharmaceuticals Announces Richie Cunningham As Chief Executive Officer
Anebulo Pharmaceuticals Q2 EPS $(0.11) Misses $(0.10) Estimate
Anebulo Pharmaceuticals (NASDAQ:ANEB) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.10) by 10 percent. This is a 26.67 percent increase over losses
Anebulo Pharmaceuticals 2Q Loss/Shr 11c >ANEB
Anebulo Pharmaceuticals 2Q Loss/Shr 11c >ANEB
Press Release: Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates AUSTIN, Texas--(BUSINESS WIRE)--February 13, 2024-- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB),
Anebulo Pharmaceuticals Filed U.S. Patent Application #20240010617: Crystalline Forms Of A Cannabinoid Receptor Type 1 (Cb1) Modulator And Methods Of Use And Preparation Thereof
Anebulo Pharmaceuticals Filed U.S. Patent Application #20240010617: Crystalline Forms Of A Cannabinoid Receptor Type 1 (Cb1) Modulator And Methods Of Use And Preparation Thereof
Buy Recommendation for Anebulo Pharmaceuticals: Promising Financial Outlook and Potential Breakthrough in Acute Cannabis Intoxication Treatment
Anebulo Pharmaceuticals GAAP EPS of -$0.10 Beats by $0.02
Anebulo Pharmaceuticals Q1 EPS $(0.10) Beats $(0.12) Estimate
Anebulo Pharmaceuticals (NASDAQ:ANEB) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.12) by 16.67 percent. This is a 9.09 percent increase over losses
Rising Cannabis Hospitalizations and Leadership Transition Boost Anebulo Pharmaceuticals' Outlook: A Buy Rating Analysis
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersNkarta (NASDAQ:NKTX) shares moved upwards by 122.3% to $3.29 during Tuesday's regular session. Nkarta's stock is trading at a volume of 55.0 million shares as of 13:30 EST. This is 13383.6% of
Purple Biotech, Nuwellis Among Healthcare Movers
MNTS, OMER and PIXY Among Mid-day Movers
Anebulo Pharmaceuticals Appoints New CEO
Anebulo Pharmaceuticals (ANEB) said Friday that it appointed Richie Cunningham as chief executive officer, succeeding Simon Allen. Cunningham has over 20 years of leadership experience, most recently
Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to Its Bd of Directors >ANEB
Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to Its Bd of Directors >ANEB
Anebulo Pharmaceuticals : Richie Cunningham Has Been Appointed as Anebulo's Chief Executive Officer >ANEB
Anebulo Pharmaceuticals : Richie Cunningham Has Been Appointed as Anebulo's Chief Executive Officer >ANEB
Benchmark Reiterates Speculative Buy on Anebulo Pharmaceuticals, Maintains $8 Price Target
Benchmark analyst Robert Wasserman reiterates Anebulo Pharmaceuticals with a Speculative Buy and maintains $8 price target.
Analysis
Price Target
No Data
